title: Mechanisms responsible for beneficial and adverse effects of rosiglitazone in a rat model of acute cardiac ischaemia-reperfusion.
abstract: Despite debate regarding its cardioprotective and pro-arrhythmic effects, the precise mechanisms of action of rosiglitazone on the heart are still unclear. We determined the mechanistic effects of rosiglitazone on cardiac function, arrhythmias and infarct size during cardiac ischaemia-reperfusion. Twenty-six rats were used. In each rat, either rosiglitazone or saline solution was administered intravenously prior to a 30 min left anterior descending coronary artery ligation and a 120 min reperfusion. Cardiac function, infarct size, myocardial levels of connexin43, Bax/Bcl-2, cytochrome c, caspase-3, caspase-8, Akt, tumour necrosis factor-α and interleukin-4 and cardiac mitochondrial function were determined. Isolated cardiomyocytes were used for studying intracellular calcium. Rosiglitazone did not alter cardiac function during the ischaemia-reperfusion periods, but increased the arrhythmia score and mortality rate, decreased the time to onset of ventricular fibrillation and prolonged the Ca2+ decay rate, in comparison to the saline-injected group (P<0.05). However, the infarct size in the rosiglitazone-injected group was reduced (P<0.05). Rosiglitazone decreased the levels of connexin43 phosphorylation, active caspase-8 and tumour necrosis factor-α, but increased the level of procaspase-3. However, levels of Bax/Bcl-2, cytochrome c, Akt and interleukin-4 and the cardiac mitochondrial function were not different between the two groups. Rosiglitazone simultaneously exerted both beneficial and adverse cardiac effects in the heart exposed to ischaemia-reperfusion. Although it decreased the infarct size via the extrinsic anti-apoptotic pathway and anti-inflammatory effects, rosiglitazone facilitated a fatal arrhythmia by decreasing connexin43 phosphorylation and prolonging the Ca2+ decay rate in ischaemia-reperfusion. The higher mortality rate in the rosiglitazone-injected group suggests that its undesirable effect was more pronounced than its benefit on infarct size reduction.
authors.affiliation: Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand.
authors.forename: Siripong
authors.initials: S
authors.lastname: Palee
authors.forename: Punate
authors.initials: P
authors.lastname: Weerateerangkul
authors.forename: Kroekkiat
authors.initials: K
authors.lastname: Chinda
authors.forename: Siriporn C
authors.initials: SC
authors.lastname: Chattipakorn
authors.forename: Nipon
authors.initials: N
authors.lastname: Chattipakorn
mesh_terms: D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced*; D002118:Calcium / Q000378:metabolism; D053148:Caspase 3 / Q000378:metabolism; D053181:Caspase 8 / Q000378:metabolism; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008929:Mitochondria, Heart / Q000502:physiology; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control; D017202:Myocardial Ischemia / Q000503:physiopathology; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D032383:Myocytes, Cardiac / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000494:pharmacology*
chemical_list: D045162:Thiazolidinediones; D000077154:Rosiglitazone; D053148:Caspase 3; D053181:Caspase 8; D002118:Calcium